Stockreport

Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares  (QNTM) 
PDF Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd™ Clinical Trial Published in Peer-Reviewed Journal TORONTO, [Read more]